Xspray Pharma
42.1 SEK +0.24%1 investor is following this company
Xspray Pharma is a pharmaceutical company with the goal of improving the quality of life for cancer patients. The company has several product candidates in the clinical development phase and plans to launch its first product on the US market during september 2024. Based on a patented technology for the amorphous formulation of drugs, the company develops product candidates with relevant medical benefits that should be able to be marketed as improved versions of established drugs for the treatment of cancer (protein kinase inhibitors, PKIs).
Read moreRevenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
XSPRAY
Daily low / high price
41.6 / 42.6
SEK
Market cap
1.32B SEK
Turnover
271.19K SEK
Volume
6.5K
Financial calendar
Interim report
2024-05-08
General meeting
2024-05-21
Interim report
2024-08-07
Interim report
2024-11-06
Annual report
2025-02-12
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 16.7 % | 16.7 % |
Ribbskottet | 12.4 % | 12.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Xspray Pharma publicerar årsredovisning 2023
Redeye: Xspray Pharma Q4 2023 - NDA-resubmission accepted by the FDA
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools